Safety of sacubitril/valsartan among older adults. Where real world data meet clinical trials results

被引：1
|
作者：
Garcia-Moll, Xavier [1 ]
Lopez, Laura [1 ]
机构：
[1] Hosp Holy Cross & St Paul, Cardiol Dept, Barcelona, Spain
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2024年 / 400卷
关键词：
HEART-FAILURE;
D O I：
10.1016/j.ijcard.2023.131706
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The real-world safety of sacubitril / valsartan among older adults (≥75): A pharmacovigilance study from the FDA data
    Lerman, Tsahi T.
    Greenberg, Noam
    Fishman, Boris
    Goldman, Adam
    Talmor-Barkan, Yeela
    Bauer, Menachem
    Goldberg, Idan
    Goldberg, Elad
    Kornowski, Ran
    Krause, Ilan
    Levi, Amos
    Cohen, Eytan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2024, 397
  • [2] Sacubitril/Valsartan: From Clinical Trials to Real-world Experience
    Joly J.M.
    Desai A.S.
    Current Treatment Options in Cardiovascular Medicine, 2018, 20 (6)
  • [3] Five Years of Sacubitril/Valsartan—a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance
    Yee Soo Kim
    Simerjeet Brar
    Natalie D’Albo
    Amit Dey
    Sachin Shah
    Sarju Ganatra
    Sourbha S. Dani
    Cardiovascular Drugs and Therapy, 2022, 36 : 915 - 924
  • [4] Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance
    Kim, Yee Soo
    Brar, Simerjeet
    D'Albo, Natalie
    Dey, Amit
    Shah, Sachin
    Ganatra, Sarju
    Dani, Sourbha S.
    CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (05) : 915 - 924
  • [5] FIVE-YEAR SAFETY ANALYSIS OF SACUBITRIL/VALSARTAN: A COMPARATIVE ANALYSIS OF ADVERSE EVENTS IN RANDOMIZED CLINICAL TRIALS AND REAL-WORLD PHARMACOVIGILANCE
    Kim, Yee Soo
    Brar, Simerjeet
    D'Albo, Natalie
    Shah, Sachin
    Ganatra, Sarju
    Dani, Sourbha
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 663 - 663
  • [6] A real-world pharmacovigilance study of sacubitril\valsartan in older people: data mining of the FDA adverse event reporting system
    Kuai, Zheng
    Li, Quan
    Zhang, Xiaoyi
    Tang, Guowen
    Ye, Yangli
    Hu, Yu
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [7] ROLE OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN ELDERLY HYPERTENSIVES WITH COMORBIDITY: FROM CLINICAL TRIALS TO REAL WORLD
    Mazza, Alberto
    Torin, Gioia
    Schiavon, Laura
    Rossetti, Ciro
    Cuppini, Stefano
    JOURNAL OF HYPERTENSION, 2021, 39 : E279 - E279
  • [8] IMPACT OF SACUBITRIL/VALSARTAN ON CLINICAL OUTCOMES IN HEART FAILURE USING REAL-WORLD DATA: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Rahhal, Alaa
    Kasem, Mohamed
    Orabi, Bassant
    Abuyousef, Safae
    Hamou, Fatima
    Mahfouz, Ahmed
    Alyafei, Sumaya
    Hassan, Emad Ahmed
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 420 - 420
  • [9] From clinical trials to real-world practice: Immune checkpoint inhibitors in older adults
    Loh, Kah Poh
    Wong, Melisa L.
    Maggiore, Ronald
    JOURNAL OF GERIATRIC ONCOLOGY, 2019, 10 (03) : 385 - +
  • [10] The evolving role of data & safety monitoring boards for real-world clinical trials
    Bunning, Bryan J.
    Hedlin, Haley
    Chen, Jonathan H.
    Ciolino, Jody D.
    Ferstad, Johannes Opsahl
    Fox, Emily
    Garcia, Ariadna
    Go, Alan
    Johari, Ramesh
    Lee, Justin
    Maahs, David M.
    Mahaffey, Kenneth W.
    Opsahl-Ong, Krista
    Perez, Marco
    Rochford, Kaylin
    Scheinker, David
    Spratt, Heidi
    Turakhia, Mintu P.
    Desai, Manisha
    JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 7 (01)
12345